[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344616-105":59,"doc-detail-344616-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","predicting-prostate-cancer-recurrence-using-an-atlas-based-tumor-control-probability-model","Predicting Prostate Cancer Recurrence Using an Atlas-Based Tumor Control Probability Model","","Recurrence after prostate cancer (PCa) radiation therapy (RT) remains a persistent challenge, as dose escalation can raise tumor control while also increasing toxicity. By leveraging tumor heterogeneity, the study investigates whether an atlas-based tumor control probability (TCP) model can identify radioresistant subvolumes at risk of low TCP to enable more personalized dose prescription. Segment-wise parameter adjustment combines registered cell-density and histopathology-informed data to improve recurrence prediction.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/predicting-prostate-cancer-recurrence-using-an-atlas-based-tumor-control-probability-model/344616/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/predicting-prostate-cancer-recurrence-using-an-atlas-based-tumor-control-probability-model/344616.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the atlas-based TCP model aim to address in prostate cancer?","Question",{"text":112,"@type":113},"It targets the persistent challenge of predicting recurrence after prostate cancer radiation therapy, especially where tumor heterogeneity leads to radioresistant regions and treatment failure risk.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patient-specific data incorporated into the model?",{"text":117,"@type":113},"Two population-based biological atlases (cell density and tumor probability) were deformably registered to each patient’s prostate contour, then anatomically segmented using histopathology findings, followed by parameter optimization from an additional histology cohort.",{"name":119,"@type":110,"acceptedAnswer":120},"Which adjustment strategy performed best for recurrence prediction?",{"text":121,"@type":113},"The approach combining segment-wise cell density with Gleason score–dependent α/β adjustments showed the strongest predictive capability, with all nine patients showing significant reductions in overall TCP values and most aligning low-TCP regions with relapsed tumor sites.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344616,1790149464,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","DOI: 10.1002/mp.70282  \nRESEARCH ARTICLE  \nPredicting prostate cancer recurrence using an atlas-based tumor control probability model  \nKazi Ridita Mahtaba1  Martin A. Ebert2,3,4 Leyla Moghaddasi5  Robert Finnegan5  George Hruby5  Annette Haworth1  \n Jeremy Booth1,5   \nYutong Zhao2  Burhan Javed6  \n1 Institute of Medical Physics, School of Physics, The University of Sydney, Camperdown, New South Wales, Australia  \n2 School of Physics, Mathematics and Computing, University of Western Australia, Crawley, Western Australia, Australia  \n3 Department of Radiation Oncology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia  \n4 Centre for Advanced Technologies in Cancer Research, Centre for Advanced Technologies in Cancer Research, Perth, Western Australia, Australia  \n5 Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, New South Wales, Australia  \n6 Genesis Care, Rockhampton Hospital, Rockhampton, Queensland, Australia  \nCorrespondence  \nKazi Ridita Mahtaba, Institute of Medical Physics, School of Physics, The University of Sydney, Camperdown NSW 2050, Australia. Email: [kmah0817@uni.sydney.edu.au](kmah0817@uni.sydney.edu.au)  \nName of the trial [registry: ClinicalTrials.gov](registry: ClinicalTrials.gov); Clinical trial registration number:  \nNCT03073278  \nAbstract  \nBackground: Recurrence following prostate cancer (PCa) radiation therapy (RT) remains a persistent challenge. Although dose escalation can improve tumor control, it often results in increased toxicity. With an understanding of tumor heterogeneity, identiﬁcation of radioresistant tumor subvolumes at risk of low tumor control probability (TCP) could provide an opportunity for personalized dose prescription to reduce risk of treatment failure without the increased risk of toxicity.  \nPurpose: The aim of this study was to evaluate the efﬁcacy of an atlasbased tumor control probability model in predicting prostate cancer recurrence by retrospectively integrating patient-speciﬁc primary radiotherapy and histopathology-informed data. A segment-wise adjustment to TCP model parameters was investigated for enhancing recurrence prediction in a patient cohort with biopsy-conﬁrmed local recurrence following deﬁnitive RT. Methods: Nine patients with biopsy proven local recurrence were selected from an ethics-approved study (NCT03073278) based on the availability of histopathology reports, dose-fractionation schedules and treatment planning data from their primary RT. Two previously-reported population-based biological atlases, one comprising a cell density data (CD-atlas) and the other tumor probability data (TP-atlas), were deformably registered to the prostate contour of each patient. Histopathology reports were retrieved for each patient, and the registered prostate atlases were anatomically segmented based on individual histopathology ﬁndings. Radiosensitivity parameters were derived from a separate patient cohort’s histology dataset using a numerical optimization method,generating a single PCa grade-independent α/β ratio, four Gleason Pattern (GP)-dependent α parameters, and nine Gleason Score (GS)-dependent α/β ratios. Three parameter adjustment approaches—cell density alone, cell density with GP-dependent α , and cell density with GS-dependent α/β, were evaluated and compared to a baseline model without adjustments. Changes in overall TCP values resulting from the adjustments were analyzed, and recurrent gross tumor volume (GTV) contours were overlaid on the TCP maps to evaluate their alignment with regions of lower TCP, assessing the model’s ability to enhance recurrence prediction.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s) . Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.  \nMed Phys. 2026;53","cbCaibeTxYuaN6eM","https://ap.wps.com/l/cbCaibeTxYuaN6eM","pdf",2229446,13,"English","# Abstract\n## Background and Purpose\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What problem does the atlas-based TCP model aim to address in prostate cancer?\",\"answer\":\"It targets the persistent challenge of predicting recurrence after prostate cancer radiation therapy, especially where tumor heterogeneity leads to radioresistant regions and treatment failure risk.\"},{\"question\":\"How were patient-specific data incorporated into the model?\",\"answer\":\"Two population-based biological atlases (cell density and tumor probability) were deformably registered to each patient’s prostate contour, then anatomically segmented using histopathology findings, followed by parameter optimization from an additional histology cohort.\"},{\"question\":\"Which adjustment strategy performed best for recurrence prediction?\",\"answer\":\"The approach combining segment-wise cell density with Gleason score–dependent α/β adjustments showed the strongest predictive capability, with all nine patients showing significant reductions in overall TCP values and most aligning low-TCP regions with relapsed tumor sites.\"}]","Predicting Prostate Cancer Recurrence Using an Atlas-Based Tumor Control Probability Model | PDF",1790054661,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f053f406deb76f63d3335132baffd92f.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33e603f42ad691eabee62ec155e59eb2.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0102bb3cbf0540e8117c7780da1c7a5f.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23e04bfd48c1c36405bda77228f66d7c.webp",980,1287]